Most “prior art” searches fail for the same reason: they’re built on keywords.
In patent work—especially in chemical and biologics—teams often treat search like a scavenger hunt: throw in a few terms, scan results, and hope the right documents surfac…

{
“error”: {
“message”: “You exceeded your current quota, please check your plan and billing details. For more information on this error, read the docs: https://platform.openai.com/docs/guides/error-codes/api-errors.”,
“type”: “insufficient_quota”,
“pa…

{
“error”: {
“message”: “You exceeded your current quota, please check your plan and billing details. For more information on this error, read the docs: https://platform.openai.com/docs/guides/error-codes/api-errors.”,
“type”: “insufficient_quota”,
“pa…

The biosimilar “patent dance” isn’t a formality—it’s the first move in a multi-year chess match.
If you’re a biologics innovator or a biosimilar applicant, the rules of engagement are familiar: exchange lists, negotiate scope, litigate, and—if you’re…

{
“error”: {
“message”: “You exceeded your current quota, please check your plan and billing details. For more information on this error, read the docs: https://platform.openai.com/docs/guides/error-codes/api-errors.”,
“type”: “insufficient_quota”,
“pa…

The Patent Dance Is No Longer a Choreography—It’s a Strategy Test
If you’re a biologics or biosimilar applicant, you already know the “patent dance” isn’t a metaphor. It’s a sequence of statutory steps that can decide whether you get to market on time—…

Big Pharma isn’t talking about it—but drug patent data is quietly becoming the most important “supply chain” input in pharma.
Here’s the uncomfortable truth: forecasting isn’t just about demand. It’s about timing—when exclusivity ends, when generics en…

Patent cliffs don’t just threaten revenue—they can quietly reshape your entire supply chain.
When a blockbuster drug’s exclusivity ends, the market doesn’t “transition” so much as it reprices overnight. Generic entrants arrive, contract terms get ren…

Generic drug makers are facing a quiet squeeze—and it’s not just one problem. It’s a stack of pressures hitting margins from every angle: pricing rules that tighten faster than costs, supply-chain friction that turns “low risk” into operational risk, a…

Branded pharma’s revenue model is under siege—and it’s not just one problem. It’s a stack.
In a recent DrugPatentWatch post, the argument is blunt: the “branded” playbook—launch a blockbuster, ride exclusivity, defend share, repeat—has been getting sys…